Cargando…
The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia
BACKGROUND: Although the diagnosis of childhood leukemia is no longer a death sentence, too many patients still die, more with acute myeloid leukemia than with acute lymphoblastic leukemia. The European Union pediatric legislation was introduced to improve pharmaceutical treatment of children, but s...
Autores principales: | Rose, Klaus, Walson, Philip D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4640230/ https://www.ncbi.nlm.nih.gov/pubmed/26604845 http://dx.doi.org/10.2147/RMHP.S63029 |
Ejemplares similares
-
Cystic Fibrosis Treatment: A Paradigm for New Pediatric Medicines, Globalization of Drug Development and the Role of the European Medicines Agency
por: Rose, Klaus, et al.
Publicado: (2015) -
Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making
por: Bakker, Elisabeth, et al.
Publicado: (2022) -
Are Regulatory Age Limits in Pediatric Melanoma Justified?
por: Rose, Klaus, et al.
Publicado: (2019) -
Psychopharmacology at the era of EMEA (European Medicines Agency)
por: Pestana, Luis Camara, et al.
Publicado: (2010) -
A bacteriophage journey at the European Medicines Agency
por: Debarbieux, Laurent, et al.
Publicado: (2015)